Search research articles
Contact Us
Filters
Showing results (161-170 of 188) with videos related to
Page
of 19
Sort By:
The Journal of Biological Chemistry
|
February 7, 1997
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells
S Kannan, M De Santis, M Lohmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
N Normanno, R Esposito Abate, M Lambiase, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
Current Oncology (Toronto, Ont.)
|
June 19, 2014
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study
M Orditura, G Galizia, N Di Martino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
S Kopetz, J Tabernero, S Lonardi, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach
E Cioli, G Suarato, R Napolitano, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
F Piscaglia, G Masi, E Martinelli, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 188) with videos related to
Sort By:
Page
of 19
The Journal of Biological Chemistry
|
February 7, 1997
Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells
S Kannan, M De Santis, M Lohmeyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 27, 2017
RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial
N Normanno, R Esposito Abate, M Lambiase, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 17, 2018
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study
E Van Cutsem, T Yoshino, H J Lenz, et al.
Current Oncology (Toronto, Ont.)
|
June 19, 2014
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma-a pilot study
M Orditura, G Galizia, N Di Martino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 1, 2026
A randomised study of encorafenib, cetuximab, and FOLFIRI versus FOLFIRI with or without bevacizumab in BRAF V600E-mutant colorectal cancer: BREAKWATER Cohort 3
S Kopetz, J Tabernero, S Lonardi, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Off-label drug use in oncology: integrating molecular and genetic analysis in an academic center's real-world approach
E Cioli, G Suarato, R Napolitano, et al.
Cancer Medicine
|
March 7, 2023
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
G Martini, D Ciardiello, V Famiglietti, et al.
ESMO Open
|
January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trial
F Piscaglia, G Masi, E Martinelli, et al.
Endocrine-Related Cancer
|
August 23, 2005
Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment
J M W Gee, A Howell, W J Gullick, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial
F Ciardiello, N Normanno, E Maiello, et al.
Page
of 19